re: Ann: Prana's PBT2 named one of Top Ne... My view from the cheap seats.
- Prana can't go it alone with AD as Prana will at the very least need a distribution partner.
- Prana can go it alone with HD as they could market that with small team to the limited number of clinics.
- HD is an orphan indication. Therefore easier path to registration and so Prana could do P3 trials with equity funding. HD community has been terrific in supporting the development thus far.
So partner PBT2 for AD, with partner fronting costs for P3 trial. With a second successful P2 trial Prana should be able to get could deal for AD.
Ann: Prana's PBT2 named one of Top Neuroscien, page-14
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $8.591K | 2.273M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 26968359 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 129390846 | 29 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |